apremilast

02/01/2023 - "Apremilast significantly improved skin-related QoL in patients with limited skin involvement with plaque psoriasis in special areas and highly impaired QoL. "
08/01/2019 - "Conclusions: Most patients with moderate psoriasis receiving apremilast had improved at 6-month follow-up. "
08/01/2023 - "However, treatment with oral apremilast resulted in complete resolution of psoriasis and significant improvement in VEN lesions after 1 month. "
05/01/2016 - "Apremilast, an oral agent, approved to treat psoriasis and PsA demonstrates moderate efficacy with an excellent safety record. "
01/01/2022 - "In routine clinical care in Germany, patients with moderate to severe plaque psoriasis benefited from apremilast treatment up to ~ 13 months, consistent with findings from clinical trials, with a good safety profile."

03/01/2017 - "Apremilast had an early onset of efficacy in patients with active psoriatic arthritis, with significantly more apremilast 30 mg twice daily than placebo recipients achieving a ≥20% improvement in modified American College of Rheumatology response criteria at week 2 in the phase 3b ACTIVE trial. "
01/01/2018 - "Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)."
06/01/2014 - "Apremilast was effective in the treatment of psoriatic arthritis, improving signs and symptoms and physical function. "
09/01/2017 - "Improvement in the Axial Symptoms and Magnetic Resonance Imaging Findings With Apremilast in Psoriatic Arthritis."
02/02/2023 - "To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). "

08/01/2012 - "The group receiving apremilast, 20 mg twice daily, displayed a significant reduction from baseline of pruritus (P=.02) and the DLQI (P=.003) at 3 months. "
01/01/2022 - "Visual analog scale of itching, and quality of life by Dermatology Life Quality Index were slightly improved in one and two apremilast-treated patients, respectively. "
05/01/2016 - "Among apremilast-treated patients, improvements in pruritus visual analog scale (VAS) scores correlated with Dermatology Life Quality Index scores (rs = 0.55 [Week 16], rs≥0.51 [Week 32]; both studies, p < 0.001). "
06/01/2020 - "Evaluation of apremilast in chronic pruritus of unknown origin: A proof-of-concept, phase 2a, open-label, single-arm clinical trial."
01/01/2019 - "We present this case for the quick and complete response of HE with apremilast, and the effective control of hepatogenic pruritus. "

03/01/2020 - "Current evidence shows that apremilast is effective for oral ulcer, the most common symptom of Behçet's disease. "
07/01/2021 - "Significant improvement in oral ulcer and BDCAF with apremilast was confirmed in real-world BD patients after 3 months. "
04/16/2015 - "Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Behçet's syndrome. "
01/01/2021 - "Apremilast is shown to be a safe and effective option approved by the FDA for oral ulcers. "
01/01/2022 - "The efficacy of apremilast was compared between patients with and without oral ulcer remission. "

03/01/2012 - "A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis."
01/01/2019 - "A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis. "
01/01/2019 - "A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis."
11/01/2023 - "Apremilast regulates several pro-inflammatory signals involved in atopic dermatitis (AD). "
05/01/2016 - "Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients."